Start Your Search
P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Presentations: 1
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
P1.01-95 - Crizotinib Treatment in 29 Advanced NSCLC Chinese Patients with ROS1 Rearrangement——A Single Chinese Cancer Institute Experience (ID 13958)
16:45 - 18:00 | Author(s): Si Sun
Approximately 1%~2% of NSCLC patients harbor ROS1 rearrangement. Crizotinib, a tyrosine kinase inhibitor that targets ALK, MET and ROS1, has shown marked antitumor activity in patients with ROS1-positive advanced NSCLC.a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 29 patients with ROS1 rearrangement advanced or metastatic NSCLC were treated with crizotinib between Apr 1st, 2016 and Feb 6th, 2018 at Shanghai Cancer Center, Fudan University. Patients were administered with oral crizotinib at dose of 250 mg twice daily.4c3880bb027f159e801041b1021e88e8 Result
The median age was 51 years old. Twenty patients (69.0%) were female. Twenty-three(79.3%) were never-smokers. Six patients (20.7%) had brain metastases. Sixteen patients (55.2%) had received chemotherapy prior to crizotinib therapy. Patients’ characteristics were showed in table 1. The ORR and DCR were 65.5% and 93.1%, respectively. The estimated median PFS has not been reached yet. Transaminases increase (15/29,51.7%), vision disorder (6/29,20.7%), blood creatinine increase (6/29,20.7%), vomiting (6/29,20.7%), fatigue (5/29,17.2%) and diarrhea (5/29,17.2%) were the most commonly reported adverse effects. Two patients (6.9%) discontinued crizotinib because of crizotinib-related vomiting, one of whom had reduced to 200mg twice daily.
Crizotinib was effective and well tolerated in Chinese patients with ROS1-positive, advanced NSCLC in real-world clinical practice.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.